Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and…
ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7 months in patients with ESR1 mutant…